207 related articles for article (PubMed ID: 31277783)
1. Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer.
Martini A; Gandaglia G; Karnes RJ; Zaffuto E; Bianchi M; Gontero P; Chlosta P; Gratzke C; Graefen M; Tilki D; Cucchiara V; Mirone V; Kneitz B; Sanchez Salas R; Van Der Poel H; Tombal B; Spahn M; Joniau TS; Montorsi F; Briganti A;
Eur Urol Oncol; 2019 Jul; 2(4):456-463. PubMed ID: 31277783
[TBL] [Abstract][Full Text] [Related]
2. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.
Rigatti P; Suardi N; Briganti A; Da Pozzo LF; Tutolo M; Villa L; Gallina A; Capitanio U; Abdollah F; Scattoni V; Colombo R; Freschi M; Picchio M; Messa C; Guazzoni G; Montorsi F
Eur Urol; 2011 Nov; 60(5):935-43. PubMed ID: 21840116
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years.
Suardi N; Gandaglia G; Gallina A; Di Trapani E; Scattoni V; Vizziello D; Cucchiara V; Bertini R; Colombo R; Picchio M; Giovacchini G; Montorsi F; Briganti A
Eur Urol; 2015 Feb; 67(2):299-309. PubMed ID: 24571959
[TBL] [Abstract][Full Text] [Related]
4. Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy.
Martini A; Fossati N; Karnes RJ; Boorjian SA; Boeri L; Bossi A; Di Muzio N; Cozzarini C; Noris Chiorda B; Gandaglia G; Robesti D; Bartkowiak D; Böhmer D; Shariat SF; Goldner G; Battaglia A; Joniau S; Berghen C; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Wiegel T; Briganti A
Eur Urol Oncol; 2021 Apr; 4(2):301-304. PubMed ID: 31810893
[TBL] [Abstract][Full Text] [Related]
5. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
6. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.
Abdollah F; Sood A; Sammon JD; Hsu L; Beyer B; Moschini M; Gandaglia G; Rogers CG; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
Eur Urol; 2015 Sep; 68(3):497-505. PubMed ID: 26119559
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P
Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
[TBL] [Abstract][Full Text] [Related]
8. Long-term cancer control after radical prostatectomy and bilateral pelvic lymph node dissection for pT3bN0M0 prostate cancer in the prostate-specific antigen era.
Fairey AS; Daneshmand S; Skinner EC; Schuckman A; Cai J; Lieskovsky G
Urol Oncol; 2014 Feb; 32(2):85-91. PubMed ID: 24183191
[TBL] [Abstract][Full Text] [Related]
9. Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes.
Gandaglia G; Soligo M; Battaglia A; Muilwijk T; Robesti D; Mazzone E; Barletta F; Fossati N; Moschini M; Bandini M; Joniau S; Karnes RJ; Montorsi F; Briganti A
Eur Urol; 2019 May; 75(5):817-825. PubMed ID: 30409676
[TBL] [Abstract][Full Text] [Related]
10. First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology.
Kang JJ; Reiter RE; Steinberg ML; King CR
Eur Urol Oncol; 2018 Oct; 1(5):378-385. PubMed ID: 31158076
[TBL] [Abstract][Full Text] [Related]
11. Patterns of Clinical Recurrence of Node-positive Prostate Cancer and Impact on Long-term Survival.
Nini A; Gandaglia G; Fossati N; Suardi N; Cucchiara V; Dell'Oglio P; Cazzaniga W; Luzzago S; Montorsi F; Briganti A
Eur Urol; 2015 Nov; 68(5):777-84. PubMed ID: 25959166
[TBL] [Abstract][Full Text] [Related]
12. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
13. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.
Malik RD; Goldberg JD; Hochman T; Lepor H
Eur Urol; 2011 Sep; 60(3):548-53. PubMed ID: 21652145
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy.
Touijer KA; Mazzola CR; Sjoberg DD; Scardino PT; Eastham JA
Eur Urol; 2014 Jan; 65(1):20-5. PubMed ID: 23619390
[TBL] [Abstract][Full Text] [Related]
15. Biochemical recurrence after robot-assisted extended pelvic lymphadenectomy for prostate cancer.
Chenam A; Ruel N; Pal S; Barlog J; Lau C; Wilson T; Yuh B
Can J Urol; 2018 Jun; 25(3):9340-9348. PubMed ID: 29900823
[TBL] [Abstract][Full Text] [Related]
16. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.
Briganti A; Joniau S; Gandaglia G; Cozzarini C; Sun M; Tombal B; Haustermans K; Hinkelbein W; Shariat SF; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):960-7. PubMed ID: 24351411
[TBL] [Abstract][Full Text] [Related]
17. Natural History of Clinical Recurrence Patterns of Lymph Node-Positive Prostate Cancer After Radical Prostatectomy.
Moschini M; Sharma V; Zattoni F; Quevedo JF; Davis BJ; Kwon E; Karnes RJ
Eur Urol; 2016 Jan; 69(1):135-42. PubMed ID: 25865061
[TBL] [Abstract][Full Text] [Related]
18. Intermediate-term cancer control outcomes in prostate cancer patients treated with robotic-assisted laparoscopic radical prostatectomy: a multi-institutional analysis.
Abdollah F; Dalela D; Sood A; Sammon J; Jeong W; Beyer B; Fossati N; Rogers CG; Diaz-Insua M; Peabody J; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
World J Urol; 2016 Oct; 34(10):1357-66. PubMed ID: 26873596
[TBL] [Abstract][Full Text] [Related]
19. Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection in Patients with Locally-advanced Prostate Cancer.
Gandaglia G; De Lorenzis E; Novara G; Fossati N; De Groote R; Dovey Z; Suardi N; Montorsi F; Briganti A; Rocco B; Mottrie A
Eur Urol; 2017 Feb; 71(2):249-256. PubMed ID: 27209538
[TBL] [Abstract][Full Text] [Related]
20. Oncologic Outcomes After Robot-assisted Radical Prostatectomy: A Large European Single-centre Cohort with Median 10-Year Follow-up.
Rajan P; Hagman A; Sooriakumaran P; Nyberg T; Wallerstedt A; Adding C; Akre O; Carlsson S; Hosseini A; Olsson M; Egevad L; Wiklund F; Steineck G; Wiklund NP
Eur Urol Focus; 2018 Apr; 4(3):351-359. PubMed ID: 28753802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
